A follow-on biologics approval pathway may be on the way. US Health and Human Services Secretary Mike Leavitt accepted Sen. Charles Schumer's (D-NY) suggestion that the Food and Drug Administration and Congress work together to formulate legislation for such a pathway.
Washington, DC (Feb 8)-A follow-on biologics approval pathway may be on the way. US Health and Human Services Secretary Mike Leavitt accepted Sen. Charles Schumer’s (D-NY) suggestion that the US Food and Drug Administration and Congress work together to formulate legislation for such a pathway.
President George W. Bush’s fiscal year 2009 budget-which proposed a 5.7% increase from FY 2008-included funding for a follow-on biologics approval pathway (see Pharmaceutical Technology’sbudget request story), which is to come from user fees. But Schumer says the pathway must also allow products to be approved as interchangeable and grant innovator products “a reasonable period of exclusivity” so that follow-on biologics, or biosimilars, can be brought to market quickly, according to the Feb. 8 Drug Industry Daily.
“It is an encouraging sign that the administration not only included this proposal in its budget, but is prepared to sit down with Congress to figure out how to make the approval process work for manufacturers and the American people,” added Schumer.
A biosimilars pathway has been on the radar for some time. In early 2007, Senators sponsoring the Biologics Price Competition and Innovation Act 2007 attempted to establish a follow-on biologics approval pathway. The pathway failed to get into the FDA Amendments Act, which passed in Sept. 2007 (see Pharmaceutical Technology’sFDAAA story). The House has also introduced similar bills, such as HR 1038.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.